Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|January 12, 2018
What Improvements Are Needed for Data Analytics in the Specialty Pharmaceutical Space?
John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, speaks about data analytics and specialty pharmacy.
Advertisement
Giannouris: Through the data standards being in place, then you actually derive or create standard analytics. So, if you have a standard data set to use and it’s broadly understood, then the analytics that can be derived and generated from that standard data set sort of becomes a standard as well.
That’s one way. It’s certainly not the only way. Different manufacturers have different data needs and a standard is not going to cover all of their needs.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
New Data Reshapes Nonstatin Lipid Therapy Choices
5